BCL2 and breast carcinoma: Here, we demonstrate that combination treatment, including SM/z-VAD and the BCL2 inhibitor ABT-263 (Navitoclax), results in cancer cytotoxic effects and synergistic effect on the standard chemotherapeutic regimen by phosphorylation of the necrosome complex in YARS-positive breast cancer (Fig. 6).